A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia

Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Lefamulin (Primary) ; Moxifloxacin
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms LEAP 2
  • Sponsors Nabriva Therapeutics
  • Most Recent Events

    • 24 Mar 2017 According to a Nabriva Therapeutics media release, company expects to complete patient enrollment in the fourth quarter of 2017 and top-line data expected in the first quarter of 2018.
    • 16 Nov 2016 According to a Nabriva Therapeutics media release, data from this trial were presented at the Infectious Disease (ID) Week 2016 Conference.
    • 16 Nov 2016 According to a Nabriva Therapeutics media release, based on the positive data of this trial company expects to submit applications for marketing approval for lefamulin for the treatment of CABP in both the United States and Europe in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top